Bolt - BOLT

Bolt Biotherapeutics Azioni (NASDAQ: BOLT)

Ultime notizie per Bolt Biotherapeutics (NASDAQ:BOLT) Azioni

Bolt Biotherapeutics

Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics Inc

BOLT

Bolt Metals Corp

Bolt Projects Holdings, Inc. - Common Stock

Bolt Projects Holdings Inc

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

<h3>Gainers</h3>
<ul>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) stock moved upwards by 89.2% to $24.05 during Wednesday's after-market session. The market value of their outstanding shares is at $642.4 million. </li>
<li>SILO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) shares moved upwards by 27.84% to $0.73. The market value of their outstanding shares is at $5.2 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares increased by 12.55% to $4.8. The market value of their outstanding shares is at $73.0 million. </li>
<li>Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) stock increased by 10.43% to $0.51. The market value of their outstanding shares is at $23.4 million. </li>
<li>Meihua Intl Medical Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MHUA#NASDAQ">MHUA</a>) stock rose 7.09% to $0.6. The company's market cap stands at $15.3 million. </li>
<li>Femasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEMY#NASDAQ">FEMY</a>) stock rose 5.56% to $0.84. The market value of their outstanding shares is at $22.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cibus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) stock fell 17.4% to $1.95 during Wednesday's after-market session. The company's market cap stands at $63.7 million. </li>
<li>Bicara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAX#NASDAQ">BCAX</a>) stock decreased by 15.86% to $9.37. The market value of their outstanding shares is at $511.2 million. </li>
<li>Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) shares fell 12.31% to $0.28. The company's market cap stands at $10.9 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) shares decreased by 7.82% to $0.48. The market value of their outstanding shares is at $8.0 million. </li>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares declined by 6.48% to $1.59. The company's market cap stands at $27.8 million. </li>
<li>Mesoblast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) stock declined by 6.33% to $10.73. The market value of their outstanding shares is at $1.3 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BCAX

CBUS

CLRB

FEMY

IMNN

KAPA

LIMN

MESO

MHUA

SILO

12 Health Care Stocks Moving In Wednesday's After-Market Session

News

Stock Split

Bolt Biotherapeutics To Effect 1-For-20 Reverse Stock Split

Lake Street analyst Chad Messer initiates coverage on Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) with a Buy rating and announces Price Target of $4.

Price Target

Initiation

Analyst Ratings

Lake Street Initiates Coverage On Bolt Biotherapeutics with Buy Rating, Announces Price Target of $4

Stifel analyst Stephen Willey maintains Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) with a Hold and lowers the price target from $1.25 to $1.

Stifel Maintains Hold on Bolt Biotherapeutics, Lowers Price Target to $1

Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.36) by 19.44 percent. This is a 3.57 percent decrease over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $1.22 million which beat the analyst consensus estimate of $767.50 thousand by 59.22 percent. This is a 76.83 percent decrease over sales of $5.27 million the same period last year.

Earnings

Earnings Beats

Bolt Biotherapeutics Q1 EPS $(0.29) Beats $(0.36) Estimate, Sales $1.22M Beat $767.50K Estimate

<ul>
<li>Conference call and webcast on Monday, May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET</li>
</ul>
- Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>), a biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced it will host a key opinion leader (KOL) conference call and webcast featuring Ecaterina Dumbrava, M.D., associate professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center and investigator on the Phase 1 dose-escalation clinical study of BDC-3042, on Monday, May 12, 2025 at 2:30 p.m. PT / 5:30 p.m. ET.
Dr. Dumbrava will discuss the results from the Phase 1 dose-escalation clinical study of BDC-3042 that were presented at the American Associates for Cancer Research (AACR) Annual Meeting that took place in April 2025. In addition, Bolt's management team will discuss BDC-3042 partnering plans, present an update on BDC-4182 clinical development, and provide an update on first quarter 2025 financial results. A live Q&amp;A will follow the prepared remarks.
 Bolt Biotherapeutics will host a conference call and webcast featuring Dr. Dumbrava on Monday, May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET. The conference call and webcast can be accessed via this link <a href="https://www.globenewswire.com/Tracker?data=hX5jpxTyPHNvgnoP_B2AszXDkiUQr9usEA6Vd8fanubiWSEanl-9_9REIcXQ8lOTcuQ-5olFT_SgYzv9E3T-FYDXgX-_G6T9SwSFqoKuMm5E04ggth9cPARKgem7pQ_AbiRb-leYCcZp-l2JAEUAWsbJuBW1xgA1ymAonmjnAWs=">https://edge.media-server.com/mmc/p/q6d3u5uv/</a>. A replay of the event will be available for a limited time under Events and Presentations in the Investors section of the Company's website at <a href="https://www.globenewswire.com/Tracker?data=Xt3epOSNwufGW_fzKBov7k20mmJRf5yXWUVCag2RVWYKCYYaoLJ7cMvucMhj-j_9hTH19bHf-OBtGJRhiwkbvlmWwhgO4aAka8TtKRs8zkOfYXMJykroTjus9htV4fIpMGeBPE6tZJdeN79K6vFZCWU7q2CeyUsGsvl-cz0o-B0U1cygGFWX8vz139J-nNkV">investors.boltbio.com/events-and-presentations</a>.

Biotech

General

Bolt Biotherapeutics Announces It Will Host Key Opinion Leader Conference Call And Webcast To Discuss BDC-3042 Phase 1 Results Monday, May 12, 2025 At 2:30 P.M. PT / 5:30 P.M. ET.

CEA-targeted ISAC elicits complete responses in mice and is well-tolerated in NHPs
PD-L1 ISAC directly activates and reprograms PD-L1-expressing myeloid cells in the TME to drive complete responses and immunological memory
REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced preclinical results from its next-generation Boltbody&#x2122; ISACs targeting CEACAM5 and PD-L1 at the American Association for Cancer Research (AACR) Annual Meeting.

Bolt Biotherapeutics Presents Preclinical Results From Next-Generation Boltbody ISACs Targeting CEACAM5 And PD-L1 At AACR Annual Meeting

HC Wainwright &amp; Co. analyst Edward White reiterates Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) from Neutral to Neutral.

Reiteration

HC Wainwright & Co. Reiterates Neutral on Bolt Biotherapeuticsto Neutral

Stifel analyst Stephen Willey maintains Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) with a Hold and lowers the price target from $1.5 to $1.25.

Stifel Maintains Hold on Bolt Biotherapeutics, Lowers Price Target to $1.25

Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.38) by 10.53 percent. This is a 10.64 percent increase over losses of $(0.47) per share from the same period last year.

Earnings Misses

Bolt Biotherapeutics Q4 2024 GAAP EPS $(0.42) Misses $(0.38) Estimate

HC Wainwright &amp; Co. analyst Edward White reiterates Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) with a Neutral.

HC Wainwright & Co. Reiterates Neutral on Bolt Biotherapeutics

Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.35) by 14.29 percent. The company reported quarterly sales of $1.141 million which missed the analyst consensus estimate of $1.263 million by 9.64 percent. This is a 54.87 percent decrease over sales of $2.528 million the same period last year.

Bolt Biotherapeutics Q3 2024 GAAP EPS $(0.40) Misses $(0.35) Estimate, Sales $1.141M Miss $1.263M Estimate

BDC-4182 demonstrated compelling anti-tumor activity and an acceptable safety profile in preclinical studies
BDC-4182 outperformed cytotoxic claudin 18.2 ADCs in syngeneic model
Learnings from BDC-1001 data suggest Boltbody&#x2122;&nbsp;ISACs with enhanced immune activation could offer greater efficacy, warranting further testing
REDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today presented updated preclinical data for BDC-4182, a next-generation Boltbody&#x2122;&nbsp;ISAC clinical candidate targeting claudin 18.2, and provided key learnings from its Phase 1 dose-escalation trial of BDC-1001 at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held in Houston, Texas from November 6-10, 2024.

Bolt Biotherapeutics Presents Updated Preclinical Data For BDC-4182 And Key Learnings From Phase 1 Dose-Escalation Trial Of BDC-1001 At SITC Annual Meeting; BDC-4182 Demonstrated Compelling Anti-tumor Activity And An Acceptable Safety Profile In Preclinical Studies

Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.48) by 16.67 percent. This is a 16.67 percent decrease over losses of $(0.48) per share from the same period last year. The company reported quarterly sales of $1.27 million which beat the analyst consensus estimate of $891.50 thousand by 43.02 percent. This is a 11.03 percent decrease over sales of $1.43 million the same period last year.

Bolt Biotherapeutics Q2 EPS $(0.56) Misses $(0.48) Estimate, Sales $1.27M Beat $891.50K Estimate

Shares of Bolt Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) fell sharply during Wednesday's session after the company reported <a href="https://www.benzinga.com/quote/BOLT/earnings">first-quarter financial results</a>.
Bolt Biotherapeutics posted a GAAP loss of 28 cents per share on sales of $5.30 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
Also, Guggenheim analyst Michael Schmidt downgraded Bolt Biotherapeutics from Buy to Neutral, while Stifel analyst Stephen Willey downgraded the stock from Buy to Hold and lowered the price target from $6 to $1.5.
Bolt Biotherapeutics shares dipped 34.4% to $0.8652 on Wednesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>AERWINS Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWIN#NASDAQ">AWIN</a>) shares surged 201% to $8.16.</li>
<li>Sintx Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) jumped 169% to $0.1449 after jumping over 41% on Tuesday. SINTX Technologies recently posted downbeat quarterly results.</li>
<li>Faraday Future Intelligent Electric Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIE#NASDAQ">FFIE</a>) jumped 87% to $0.5336 after jumping around 368% on Tuesday.</li>
<li>Edible Garden AG Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDBL#NASDAQ">EDBL</a>) climbed 53.2% to $6.54 following first-quarter results.</li>
<li>iPower Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPW#NASDAQ">IPW</a>) gained 53% to $1.36 after the company reported better-than-expected third-quarter financial results.</li>
<li>Selina Hospitality PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNA#NASDAQ">SLNA</a>) jumped 51% to $0.0850.</li>
<li>Greenwave Technology Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWAV#NASDAQ">GWAV</a>) shares gained 41% to $0.0627 after surging 7% on Tuesday.</li>
<li>Complete Solaria, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSLR#NASDAQ">CSLR</a>) gained 30.6% to $0.90. Complete Solaria signed a term sheet to eliminate Carlyle debt.</li>
<li>OptimizeRx Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) jumped 24% to $13.03 following upbeat quarterly results.</li>
<li>Blue Star Foods Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSFC#NASDAQ">BSFC</a>) rose 23% to $0.0686.</li>
<li>monday.com Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) jumped 21.5% to $220.93 after the company reported better-than-expected first-quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>Telos Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLS#NASDAQ">TLS</a>) gained 21.4% to $3.85.</li>
<li>BioCryst Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) rose 20% to $6.44.</li>
<li>Arcutis Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) rose 16.5% to $9.47 after the company reported better-than-expected first-quarter financial results.</li>
<li>Dolphin Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLPN#NASDAQ">DLPN</a>) rose 15.4% to $1.2999 after the company reported a year-over-year increase in first-quarter financial results.</li>
<li>Codere Online Luxembourg, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDRO#NASDAQ">CDRO</a>) jumped 14.3% to $7.98 following first-quarter results.</li>
<li>Nutriband Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) gained 13.5% to $4.34.</li>
<li>Riskified Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSKD#NYSE">RSKD</a>) jumped 12.8% to $6.05 following upbeat results.</li>
<li>Cabaletta Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) gained 12.8% to $12.66 following first-quarter results.</li>
<li>Jeffs&#8217; Brands Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>) jumped 12% to $0.2530.</li>
<li>B&amp;G Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGS#NYSE">BGS</a>) rose 11.5% to $9.53.</li>
<li>Crown ElectroKinetics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRKN#NASDAQ">CRKN</a>) shares rose 11.2% to $0.0529.</li>
<li>Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) gained 8.1% to $0.0637 after adding around 12% on Tuesday.</li>
<li>Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) rose 6% to $142.18 after Morgan Stanley maintained an Overweight rating on the stock and raised its price target from $128 to $152.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares fell 63.9% to $0.8199 after the company reported pricing of $2.25m public offering.</li>
<li>Yield10 Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTEN#NASDAQ">YTEN</a>) fell 49.4% to $2.66 after the company reported delisting from the Nasdaq.</li>
<li>Aethlon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) fell 45.8% to $0.4604 after the company announced pricing of $4.7 million public offering.</li>
<li>Pixelworks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXLW#NASDAQ">PXLW</a>) dipped 40.2% to $1.1186 after the company issued soft second-quarter guidance.</li>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) shares fell 31.9% to $33.22 following a 60% surge on Tuesday.</li>
<li>Koss Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOSS#NASDAQ">KOSS</a>) dipped 31% to $4.24.</li>
<li>VirTra, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTSI#NASDAQ">VTSI</a>) shares fell 30% to $11.49 after the company reported worse-than-expected first-quarter financial results.</li>
<li>MicroCloud Hologram Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLO#NASDAQ">HOLO</a>) dipped 30.3% to $2.25.</li>
<li>SunPower Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWR#NASDAQ">SPWR</a>) shares fell 29.6% to $3.0896. Wolfe Research analyst Steve Fleishman downgraded SunPower from Peer Perform to Underperform.</li>
<li>Intrusion Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) shares declined 28.7% to $1.84 after the company reported downbeat first-quarter sales.</li>
<li>DLocal Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLO#NASDAQ">DLO</a>) fell 27.5% to $9.84 after the company reported weaker-than-expected first-quarter earnings and said there is a greater likelihood of coming in towards the lower end of its guidance range.</li>
<li>AMC Entertainment Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) fell 26.3% to $5.04 after jumping 32% on Tuesday.</li>
<li>Maxeon Solar Technologies, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAXN#NASDAQ">MAXN</a>) declined 25% to $2.7550.</li>
<li>The Oncology Institute, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) fell 24.4% to $0.6798 following weak quarterly results.</li>
<li>Cheetah Net Supply Chain Service Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNT#NASDAQ">CTNT</a>) shares fell 23.2% to $4.92 after jumping 442% on Tuesday. The company priced a follow-on offering for gross proceeds of $8.19 million.</li>
<li>Nortech Systems Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSYS#NASDAQ">NSYS</a>) fell 21.1% to $11.97. Nortech Systems is expected to hold a conference call on Thursday, May 16, to discuss the company&#8217;s first quarter financial results.</li>
<li>Virgin Galactic Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NASDAQ">SPCE</a>) fell 16.5% to $1.06.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) declined 12.5% to $11.80.</li>
<li>Pulse Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) declined 12.1% to $6.74. Pulse Biosciences named Burke T. Barrett as President and Chief Executive Officer.</li>
<li>iRobot Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRBT#NASDAQ">IRBT</a>) fell 11.8% to $11.24.</li>
<li>BlackBerry Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) fell 10.2% to $3.11.</li>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) fell 9.9% to $4.8000.</li>
<li>NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) dipped 9.5% to $5.24. New reports indicate the company on Wednesday launched its first vehicle under its new Onvo brand.</li>
<li>Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) fell 8.7% to $10.22.</li>
<li>Petróleo Brasileiro S.A. &#8211; Petrobras (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBR#NYSE">PBR</a>) shares fell 8.3% to $15.30. Brazil's President Luiz Inacio Lula da Silva fired Jean Paul Prates, the CEO of Petrobras, following a dispute over dividend.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/05/38844468/jim-cramer-this-industrial-company-is-absolutely-terrific-recommends-buying-modine-manufacturing">Jim Cramer: This Industrial Company Is &#8216;Absolutely Terrific&#8217;, Recommends Buying Modine Manufacturing</a>

Intraday Update

Markets

AEMD

ARQT

AWIN

BCRX

BSFC

CABA

CDRO

CRKN

CSLR

CTNT

DELL

DLPN

EDBL

FFIE

GWAV

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

INTZ

IRBT

JFBR

KOSS

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

MNDY

NOVA

NSYS

NTRB

NVAX

OPRX

PEGY

PLSE

PXLW

RIVN

RSKD

SINT

SLNA

SPCE

SPWR

VRPX

VTSI

YTEN

Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Leerink Partners analyst Daina Graybosch downgrades Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) from Outperform to Market Perform and lowers the price target from $3 to $1.

Downgrades

Leerink Partners Downgrades Bolt Biotherapeutics to Market Perform, Lowers Price Target to $1

<h3>Gainers</h3>
<ul>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock moved upwards by 136.2% to $0.13 during Wednesday's regular session. The company's market cap stands at $15.9 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>T2 Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) shares moved upwards by 45.55% to $6.06. The company's market cap stands at $81.9 million. </li>
<li>Nutriband (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) shares rose 25.9% to $4.67. The company's market cap stands at $51.2 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) shares increased by 25.64% to $2.89. The company's market cap stands at $2.5 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) shares moved upwards by 22.8% to $12.87. The market value of their outstanding shares is at $234.0 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock increased by 20.57% to $1.0. The market value of their outstanding shares is at $50.7 million. As per the news, the Q1 earnings report came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) stock decreased by 67.0% to $0.76 during Wednesday's regular session. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock fell 50.35% to $0.42. The company's market cap stands at $1.1 million. </li>
<li>Yield10 Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTEN#NASDAQ">YTEN</a>) stock decreased by 37.84% to $3.27. The company's market cap stands at $2.1 million. </li>
<li>Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) shares declined by 33.12% to $0.88. The company's market cap stands at $33.6 million. The company's, Q1 earnings came out yesterday. </li>
<li>Oncology Institute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) shares fell 18.91% to $0.73. The market value of their outstanding shares is at $54.2 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) shares declined by 18.27% to $1.61. The market value of their outstanding shares is at $3.6 million. The company's, Q1 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BBLG

EYEN

TCON

TTOO

12 Health Care Stocks Moving In Wednesday's Intraday Session

Jones Trading analyst Soumit Roy downgrades Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) from Buy to Hold.

Jones Trading Downgrades Bolt Biotherapeutics to Hold

Health Care

Press Releases

Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.

Bolt Biotherapeutics to Participate in Upcoming March Conferences

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025

Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates

Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Abpro Hldgs

Ainos

Aprea Therapeutics

BioCardia

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Cosciens Biopharma

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Equillium

Genprex

GT Biopharma

HCW Biologics

Immuron Limited - American Depositary Shares

Immuron

Kairos Pharma

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

Neuphoria Therapeutics Inc. - Common Stock

Neuphoria Therapeutics

NextCure

BiomX

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

Portage Biotech

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

XTL Biopharmaceuticals Ltd. - American Depositary Shares

XTL Biopharmaceuticals

Lake Street

Stifel

Leerink Partners

SVB Leerink

Morgan Stanley

Bolt Technology

Screenshot 2024-12-06 at 6.41.42 PM

Emerging Markets

Commodities

Movers & Shakers

PACIFIC RIM COBALT CORP by Pacific Rim Cobalt Corp.

Comments

Bolt Biotherapeutics

Notizie

Ultime notizie per Bolt Biotherapeutics (NASDAQ:BOLT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO